Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2023-06-08 Environmental & Social …
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
ABIVAX: L’action Abivax intégrée dans les Indices MSCI
Environmental & Social Information Classification · 1% confidence The document is a press release dated June 8, 2023, announcing that Abivax's stock has been integrated into the MSCI indices since June 1, 2023. This type of announcement, which communicates a significant corporate event (index inclusion) that impacts investor perception and market positioning, is typically released as an official press release. It is not a formal regulatory filing like a 10-K, an earnings report (ER), or a detailed management discussion (MDA). Since it is an announcement of a corporate event/status change, and it doesn't fit the specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (CAP), it falls best under the general category for regulatory/corporate announcements that are not otherwise specified, which is Regulatory Filings (RNS). The document length (6784 chars) is substantial enough to be a full announcement, not just a brief RPA.
2023-06-08 French
Abivax stock included in MSCI Indexes
Regulatory Filings Classification · 1% confidence The document is a short news release dated June 8, 2023, announcing that 'Abivax stock [is] included in MSCI Indexes'. It is disseminated via EQS-News, which typically handles regulatory news and press releases. The content is an announcement of a corporate event (index inclusion) rather than a comprehensive financial report (like 10-K or IR) or a specific regulatory filing form. Since it is a general corporate announcement that doesn't fit the specific categories like ER, DIV, or CAP, and it is not an announcement *about* a report (RPA), the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory news and miscellaneous announcements.
2023-06-08 English
Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting
AGM Information Classification · 1% confidence The document explicitly states in the title and body that it is releasing the results of the 'ordinary and extraordinary general meeting' held on June 5, 2023. The keywords 'AGM/EGM' and the content confirming shareholder approval of resolutions strongly indicate this is related to an Annual General Meeting (AGM). Since the document is an announcement detailing the results of the vote, the most appropriate classification is AGM-R (AGM Information/Results). It is not a DEF 14A (which focuses on remuneration) or a DVA (which focuses purely on voting results, although this document contains them, the context is the overall AGM event). Given the focus on the meeting itself and its outcomes, AGM-R is the best fit.
2023-06-08 English
Abivax appoints Ida Hatoum as Chief People Officer
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new executive, Ida Hatoum, as Chief People Officer. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). It is not a comprehensive financial report (10-K, IR), an earnings release (ER), or a proxy statement (DEF 14A/PSI). The format is a standard corporate news release distributed via EQS-News.
2023-06-08 English
ABIVAX: Ida Hatoum est nommée Directrice des Ressources Humaines d’Abivax
Board/Management Information Classification · 1% confidence The document is a press release dated June 6, 2023, announcing the appointment of Ida Hatoum as the new Chief Human Resources Officer (Directrice des Ressources Humaines) for Abivax. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition of 'Board/Management Information'. The content focuses entirely on the executive appointment, responsibilities, and background, not on financial results (ER/IR), regulatory filings (10-K/AR), or shareholder voting (DVA/PSI). Therefore, the appropriate code is MANG.
2023-06-06 French
ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 30.04.23.
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Nombre d'actions composant le capital social et nombre total de droits de vote' (Number of shares comprising the share capital and total number of voting rights). It explicitly references French regulatory requirements: 'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des Marchés Financiers (AMF)'. This type of mandatory disclosure, detailing the total share count and voting rights as of a specific date (May 24, 2023, referencing data as of April 30, 2023), is a specific regulatory filing related to share capital structure and ownership thresholds. While it is a regulatory announcement, it is not a general RNS, nor is it a major shareholding notification (MRQ) which usually reports a change crossing a threshold. It is a routine update on the capital structure. Given the specific nature of reporting total voting rights and share capital as required by the AMF, this fits best under the general 'Regulatory Filings' (RNS) category as a specific, non-standard report, or potentially a 'Share Issue/Capital Change' (SHA) if it were announcing a change, but here it is a periodic statement of the current state. Since there is no specific code for 'Total Voting Rights Disclosure', and it is a formal regulatory update, RNS is the most appropriate fallback for a specific, non-core financial report filing. However, looking closely at the definitions, it is a formal disclosure about the capital structure. Since it is a formal, periodic disclosure required by the regulator, and not a general announcement of a report, RNS is the best fit among the provided options for a specific regulatory disclosure that isn't 10-K, IR, or ER.
2023-05-24 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.